Advanced Drug Delivery Systems Global Market Report 2024

The advanced drug delivery systems market size has grown strongly in recent years. It will grow from $256.43 billion in 2023 to $272.61 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The expansion observed in the historical period can be attributed to factors such as improved patient compliance, drug patent expirations, the adoption of personalized medicine, the prevalence of chronic diseases, and the development of biologics and large molecule drugs.

The advanced drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $348.27 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The anticipated growth in the forecast period can be attributed to the adoption of patient-friendly routes of administration, a focus on rare diseases, the integration of digital health, patient-centric drug development, the influence of telehealth, advancements in gene therapy and RNA therapeutics, the use of exosome-based drug delivery, and the incorporation of remote monitoring devices. Major trends in the forecast period include advancements in nanotechnology, the development of smart drug delivery systems, the use of 3D printing in drug formulations, the integration of artificial intelligence, and a focus on sustainable drug delivery.

The anticipated rise in chronic conditions is poised to drive the expansion of the advanced drug delivery systems market. Chronic conditions, persisting for a year or longer and necessitating ongoing medical care, are attributed to various risk behaviors such as tobacco use, exposure to secondhand smoke, poor nutrition, physical inactivity, and excessive alcohol use. Advanced drug delivery systems play a crucial role in precisely delivering therapeutic agents to specific sites affected by chronic conditions, enhancing drug effectiveness, and minimizing side effects. For example, as per May 2023 data from The United Nations (UN), chronic diseases account for seven out of 10 deaths in the US, causing over 1.7 million fatalities annually. Consequently, the increasing prevalence of chronic conditions underpins the growth of the advanced drug delivery systems market.

The shifting trend towards personalized medicine is anticipated to fuel the advancement of the advanced drug delivery systems market. Personalized medicine, also known as precision medicine, considers individual differences in genes, environments, and lifestyles for tailored medical care. Advanced drug delivery systems are instrumental in directing drugs precisely to diseased cells or tissues, reducing exposure to healthy organs and minimizing side effects. In February 2023, according to the Personalized Medicine Coalition, personalized drugs constituted 34% of new pharmaceuticals approved by the US Food and Drug Administration in 2022, marking a significant increase from the previous eight years. Therefore, the growing inclination towards personalized medicine is a driving force for the advanced drug delivery systems market.

Technological advancements represent a prominent trend in the advanced drug delivery systems market, with major companies embracing new technologies to maintain their market positions. In June 2023, Shilpa Medicare Limited, an India-based manufacturer and supplier of API and formulations, introduced Molshil, the world's first oral thin film formulation of a pediatric dose of paracetamol. This innovative paracetamol formulation boasts high palatability, ease of administration, and eliminates some disadvantages associated with pediatric formulations.

Major companies in the advanced drug delivery systems market are adopting strategic partnerships to facilitate more effective brain-targeted medication delivery. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits. In June 2021, The Wyss Institute for Biologically Inspired Engineering of Harvard University announced an industry partnership with Bristol-Myers Squibb Company, Eisai Inc., and H. Lundbeck A/S to enhance methods for delivering medications through the blood-brain barrier (BBB). The initiative aims to discover transporter-targeted proteins in the BBB and produce antibody molecules to aid future medicines in reaching the brain.

In May 2022, Halozyme Therapeutics Inc., a US-based biopharmaceutical company, acquired Antares Pharma Inc., a US-based specialty pharmaceutical firm. Through this acquisition, Halozyme aims to strengthen its position as a top drug delivery firm, expanding its approach to covering specialized goods with its best-in-class auto-injector technology and specialty commercial business.

Major companies operating in the advanced drug delivery systems market report are Pfizer Inc., Johnson and Johnson Services Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, F. Hoffmann-La Roche Ltd., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, 3M Company, Medtronic plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Amgen Inc., Merck Group, Becton Dickinson and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Boston Scientific Corporation, Mylan N.V., Astellas Pharma Inc., Catalent Inc., Nipro Corporation, AptarGroup Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Insulet Corporation.

North America was the largest region in the advanced drug delivery systems market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced drug delivery systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the advanced drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The main types of advanced drug delivery systems include oral drug delivery systems, injection-based drug delivery systems, inhalation or pulmonary drug delivery systems, transdermal drug delivery systems, transmucosal drug delivery systems, carrier-based drug delivery systems, and others. The oral drug delivery system involves introducing a chemical through the mouth or into the gastrointestinal tract for systemic activity. Carrier types in these systems include liposomes, nanoparticles, microspheres, monoclonal antibodies, and others. Various technologies, such as prodrugs, implants, intrauterine devices, targeted drug delivery, polymeric drug delivery, and others, are employed. These delivery systems find applications in indications such as cardiovascular diseases, oncology, urology, diabetes, central nervous system (CNS) disorders, ophthalmology, inflammatory diseases, infections, and more. They are utilized by hospitals, specialized clinics, and clinical research and development centers.

The advanced drug delivery systems research report is one of a series of new reports that provides advanced drug delivery systems market statistics, including the advanced drug delivery systems industry's global market size, regional shares, competitors with advanced drug delivery systems market share, detailed advanced drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the advanced drug delivery systems industry. This advanced drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The advanced drug delivery systems market consists of revenues earned by entities by providing stimuli-responsive drug delivery systems, sustained drug delivery systems, targeted drug delivery systems, and nanoparticle-based drug delivery systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced drug delivery systems market also consists of sales of fentanyl transdermal patches, albuterol inhalers, and hydrogels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.